Key Players in the Taiwan Chronic Venous Insufficiency Market | Insights 2026

Key Players in the Taiwan Chronic Venous Insufficiency Market

The Taiwan Chronic Venous Insufficiency (CVI) market is a combination of global medical device leaders and therapeutic giants, all competing for a higher market share through advanced minimally invasive technologies and specialized venoactive therapies. Major companies in the market include Medtronic, Servier, Boston Scientific, BD (Becton, Dickinson and Company), PW Clinic and Getz Healthcare.

Taiwan Chronic Venous Insufficiency Market Overview

According to 6Wresearch, the Taiwan Chronic Venous Insufficiency market is expanding further, due to growing awareness levels and the prevalence of vascular disorders among the aging population. CVI is a disorder that affects blood flow from the leg veins to the heart, and severely affects the quality of life through symptoms like varicose veins, edema, and skin ulcers.

The growth of healthcare infrastructure in Taiwan is driving the growth of this market, with initiatives to innovate and develop special treatments for such disorders gaining traction. Organizations are investing heavily in R&D, particularly in endogenous thermal ablation, medical adhesives, and advanced sclerotherapy, for individuals suffering from Chronic Venous Insufficiency.

Competitive Landscape

The competitive landscape of the Taiwan Chronic Venous Insufficiency Industry is categorized by multinational medical technology companies that use their superior R&D capabilities to bring innovations in the treatment of venous reflux, alongside an expanding sector of specialized vascular clinics and pharmaceutical providers. Moreover, the rise in the number of local and international players has resulted in innovations in CVI care for patients.

Below is the list of leading players in the Taiwan Chronic Venous Insufficiency Market:

1. Medtronic Taiwan

Medtronic is a global leader in medical technology, providing the VenaSeal closure system and ClosureFast radiofrequency ablation, which are critical for CVI treatment.

2. Servier Taiwan

Servier is a primary pharmaceutical player, offering Daflon, a widely prescribed micronized purified flavonoid fraction used to manage symptoms of chronic venous disease.

3. BD (Becton, Dickinson and Company) Taiwan

BD specializes in peripheral intervention, providing the Venous Stent specifically designed for the iliofemoral veins to treat obstructive venous conditions.

4. Boston Scientific Taiwan

Boston Scientific offers a comprehensive portfolio of peripheral vascular products, including catheters and imaging technologies used in complex venous interventions.

5. Cook Medical Taiwan

Cook Medical provides a range of minimally invasive venous products, including the Zilver Vena, focusing on durability and flexibility in treating CVI.

6. Getz Healthcare Taiwan

Getz Healthcare plays a critical role in bringing international CVI medical devices and specialized surgical equipment to the Taiwanese market.

7. Merit Medical Taiwan

Merit Medical provides essential tools for sclerotherapy and venous access, supporting physicians in performing minimally invasive procedures for varicose veins.

8. PW Clinic

PW Clinic is a specialized leader in clinical CVI care, pioneering the use of the VenaSeal closure system and advanced laser therapy.

9. AngioDynamics

AngioDynamics provides the VenaCure EVLT system, a prominent endogenous laser ablation technology utilized across major vascular centres.

10. Teleflex Taiwan

Teleflex offers specialized vascular access and closure products that support the procedural needs of clinicians treating chronic venous insufficiency.

Key Players in the Taiwan Chronic Venous Insufficiency Market: FAQs